Jack Lodge, Commissioning Editor of Bioanalysis, and Neil Spooner, Editor-in-Chief, speak to Fumin Li.
Fumin Li obtained his PhD in analytical chemistry from Iowa State University (ISU) in 2004. From 2004 to 2006, Li was a postdoctoral fellow at Pacific Northwest National Laboratory (PNNL), building ion mobility-mass spectrometry (i.e., IMS-TOFMS or FAIMS-TOFMS) and applying it for high-throughput proteomics. Li has more than 16 years of technical and scientific operation experience in two leading contract research organizations (CROs), LabCorp (formerly Covance) and PPD (now part of Thermo Fisher Scientific), which focuses on LC-MS-based quantitative bioanalysis. Li provides scientific oversight for method development/transfer and validation for hundreds of LC–MS/MS methods to support regulated bioanalysis of small molecules, peptides, oligonucleotides, biotherapeutics and biomarkers for investigational new drug applications (INDs), new drug applications (NDAs) and abbreviated new drug applications (ANDAs). filings with many approved drugs on the market. He interacts with regulators (e.g., US FDA) and regulatory agencies to address regulatory inquiries. Li is instrumental in laboratory operations with a track record of success in employee engagement/development, excellent client services and exceptional financial performance. He is the founder of Biollege LLC, providing consultation in LC–MS-based (regulated and nonregulated) bioanalysis to biotechnology and pharmaceutical companies and manufacturers of analytical instruments and/or consumables.